Ashwagandha and Cortisol: What the RCTs Show vs the Instagram Hype

Ashwagandha genuinely works. The problem is almost nobody talks about who it works for — and there's a real chance that's not you.

Every second supplement ad on Instagram right now promises ashwagandha will crush your cortisol and fix your stress. The research backs the cortisol claim. What it doesn't back is the implication that this applies universally, to everyone, regardless of their actual stress level. Let's look at exactly who the trials recruited, because that detail changes everything.

What the research actually shows

A 2024 systematic review and meta-analysis by Arumugam et al. published in Explore pooled nine randomised controlled trials involving 558 patients and found a statistically significant reduction in serum cortisol with ashwagandha supplementation compared to placebo (mean difference: −2.58), alongside significant improvements on the Perceived Stress Scale and Hamilton Anxiety Scale. This is solid, aggregated evidence. Ashwagandha does something real to the stress response.

But look closely at how the underlying trials recruited participants. A 2019 randomised, double-blind, placebo-controlled study by Lopresti et al. published in Medicine specifically enrolled adults with self-reported high stress, not a general population sample. Sixty stressed adults took 240mg of standardised ashwagandha extract daily for 60 days. The results were strong: significantly reduced anxiety scores and a statistically significant reduction in morning cortisol (p<.001) compared to placebo. The mechanism proposed was moderation of the hypothalamus-pituitary-adrenal axis, the body's central stress response system.

A 2016 double-blind, randomised, placebo-controlled trial by Choudhary et al. published in the Journal of Evidence-Based Complementary and Alternative Medicine again specifically recruited adults under chronic stress — 52 participants, all screened for chronic stress before enrollment. Ashwagandha at 300mg twice daily produced significant improvements in perceived stress, food cravings, happiness measures, and body weight management over 8 weeks.

Notice the pattern: every major trial with strong, significant cortisol reduction specifically recruited people who were already chronically stressed. This isn't a minor methodological detail, it's the entire story. In someone with an already-elevated, dysregulated HPA axis, ashwagandha has a measurable lever to pull. In someone with a normally functioning stress response and unremarkable baseline cortisol, there's simply less room for the intervention to produce a detectable effect, the physiological ceiling that limits how much a compound can improve something that isn't actually elevated.

What this means for you

If you're a well-trained athlete with a structured routine, adequate sleep, and no significant chronic life stress, taking ashwagandha because an influencer said it lowers cortisol is applying a clinically stressed-population intervention to a physiological profile the trials didn't test. You may feel subjectively calmer, placebo and general adaptogenic effects are real, but you're unlikely to see the dramatic biomarker shifts reported in these trials, because your starting cortisol likely isn't elevated the way trial participants' was.

If you're managing genuine chronic stress — disrupted sleep, high subjective stress, elevated resting heart rate, difficulty recovering between training sessions — the evidence for ashwagandha at doses of 240–600mg daily (standardised root extract) is genuinely strong and worth considering. This is where the research actually applies.

The honest way to know which category you're in: track your own subjective stress and, if accessible, morning resting heart rate or heart rate variability over a couple of weeks before starting. If those numbers already look healthy, ashwagandha isn't likely to be the highest-leverage intervention available to you, sleep, training load management, and recovery protocols will move the needle more.

The biotype angle

Endomorphs with elevated baseline cortisol — often accompanying higher stress-related fat storage patterns — are the biotype most likely to see the effects documented in these trials. The Choudhary trial's body weight and food craving findings are particularly relevant here, since chronic cortisol elevation is directly linked to increased appetite and abdominal fat storage.

Ectomorphs with a normally functioning HPA axis and lower baseline cortisol are the group least likely to see meaningful biomarker change, per the trial recruitment pattern above. Money and attention are probably better spent elsewhere for this biotype unless genuine chronic stress is present.

Mesomorphs in heavy training blocks with accumulating fatigue and disrupted sleep sit in the middle — training-induced stress can genuinely elevate cortisol similarly to the chronic-stress populations studied, making ashwagandha a reasonable consideration specifically during high-load training phases, rather than as a year-round staple.

Download the free Biotype Guide at milenium.com.au
→ milenium.com.au

References:
1. Arumugam V et al. Effects of Ashwagandha on stress and anxiety: A systematic review and meta-analysis. Explore, 2024. DOI: 10.1016/j.explore.2024.103062
2. Lopresti AL et al. An investigation into the stress-relieving and pharmacological actions of an ashwagandha extract. Medicine, 2019. DOI: 10.1097/MD.0000000000017186
3. Choudhary D et al. Body Weight Management in Adults Under Chronic Stress Through Treatment With Ashwagandha Root Extract. Journal of Evidence-Based Complementary and Alternative Medicine, 2016. DOI: 10.1177/2156587216641830